Peptide-Based Therapeutics for Neurodegeneration

Peptide-Based Therapeutics for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Peptide-Based Therapeutics for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Peptide</td>
<td>Origin</td>
</tr>
<tr>
<td class="label">TAT (Trans-Activator of Transcription)</td>
<td>HIV-1</td>
</tr>
<tr>
<td class="label">Penetratin</td>
<td>Antennapedia homeodomain</td>
</tr>
<tr>
<td class="label">Polyarginine (R9)</td>
<td>Synthetic</td>
</tr>
<tr>
<td class="label">Transportan</td>
<td>Chimeric</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Peptide Approach</td>
</tr>
<tr>
<td class="label">[Aβ](/proteins/amyloid-beta)</td>
<td>KLVFF-derived inhibitors</td>
</tr>
<tr>
<td class="label">[Tau](/proteins/tau)</td>
<td>PHF6-blocking peptides</td>
</tr>
<tr>
<td class="label">[α-synuclein](/proteins/alpha-synuclein)</td>
<td>Aggregation blockers</td>
</tr>
<tr>
<td class="label">[TDP-43](/proteins/tdp-43)</td>
<td>RNA-binding domain peptides</td>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">High specificity</td>
<td>Target specific protein-protein interactions</td>
</tr>
<tr>
<td class="label">Low tissue accumulation</td>
<td>Reduced risk of long-term toxicity</td>
</tr>
<tr>
<td class="label">Reduced off-target effects</td>
<td>Clean pharmacological profile</td>
</

...

Peptide-Based Therapeutics for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Peptide-Based Therapeutics for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Peptide</td>
<td>Origin</td>
</tr>
<tr>
<td class="label">TAT (Trans-Activator of Transcription)</td>
<td>HIV-1</td>
</tr>
<tr>
<td class="label">Penetratin</td>
<td>Antennapedia homeodomain</td>
</tr>
<tr>
<td class="label">Polyarginine (R9)</td>
<td>Synthetic</td>
</tr>
<tr>
<td class="label">Transportan</td>
<td>Chimeric</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Peptide Approach</td>
</tr>
<tr>
<td class="label">[Aβ](/proteins/amyloid-beta)</td>
<td>KLVFF-derived inhibitors</td>
</tr>
<tr>
<td class="label">[Tau](/proteins/tau)</td>
<td>PHF6-blocking peptides</td>
</tr>
<tr>
<td class="label">[α-synuclein](/proteins/alpha-synuclein)</td>
<td>Aggregation blockers</td>
</tr>
<tr>
<td class="label">[TDP-43](/proteins/tdp-43)</td>
<td>RNA-binding domain peptides</td>
</tr>
<tr>
<td class="label">Advantage</td>
<td>Description</td>
</tr>
<tr>
<td class="label">High specificity</td>
<td>Target specific protein-protein interactions</td>
</tr>
<tr>
<td class="label">Low tissue accumulation</td>
<td>Reduced risk of long-term toxicity</td>
</tr>
<tr>
<td class="label">Reduced off-target effects</td>
<td>Clean pharmacological profile</td>
</tr>
<tr>
<td class="label">Chemical versatility</td>
<td>Multiple modification strategies available</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>CPPs enable CNS delivery</td>
</tr>
<tr>
<td class="label">Biocompatibility</td>
<td>Often derived from endogenous sequences</td>
</tr>
<tr>
<td class="label">Challenge</td>
<td>Mitigation Strategy</td>
</tr>
<tr>
<td class="label">Short half-life</td>
<td>PEGylation, D-amino acids, cyclization</td>
</tr>
<tr>
<td class="label">Poor oral bioavailability</td>
<td>Parenteral, intranasal, or transdermal routes</td>
</tr>
<tr>
<td class="label">High manufacturing costs</td>
<td>Recombinant production, solid-phase synthesis optimization</td>
</tr>
<tr>
<td class="label">Potential immunogenicity</td>
<td>Humanized sequences, PEGylation</td>
</tr>
<tr>
<td class="label">Limited tissue distribution</td>
<td>Targeted delivery systems, CPPs</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Subcutaneous</td>
<td>Self-administration, sustained release</td>
</tr>
<tr>
<td class="label">Intranasal</td>
<td>Direct nose-to-brain delivery</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Rapid systemic distribution</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct CSF access</td>
</tr>
<tr>
<td class="label">Convection-enhanced</td>
<td>Broad brain distribution</td>
</tr>
<tr>
<td class="label">Peptide</td>
<td>Target</td>
</tr>
<tr>
<td class="label">CAD106</td>
<td>Aβ</td>
</tr>
<tr>
<td class="label">ACI-35</td>
<td>Aβ</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>GLP-1R</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>GLP-1R</td>
</tr>
</table>

Introduction

Peptide Based Therapeutics For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Peptide therapeutics represent a rapidly growing class of drugs for neurodegenerative diseases, bridging the gap between small molecules and large biologics. Peptides offer high specificity for target engagement while potentially avoiding some limitations of both approaches.^[1] This page covers peptide drugs and peptide-based approaches in development for Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and related disorders. [@lau2018]

The global peptide therapeutics market is projected to reach $50 billion by 2025, with neurodegenerative applications representing a significant growth area.^[2] Unlike small molecules that often lack specificity, peptides can be designed to target protein-protein interactions central to neurodegeneration pathology. [@guidotti2017]

Classes of Neuroprotective Peptides

Cell-Penetrating Peptides (CPPs)

Cell-penetrating peptides enable delivery of therapeutic cargo across the [blood-brain barrier](/entities/blood-brain-barrier) (BBB) and into target cells.^[3] [@wang2015]

CPPs can deliver neuroprotective proteins, antisense oligonucleotides, and small molecules directly to [neurons](/entities/neurons) and glia.^[4] [@leung2020]

Neurotrophic Peptide Mimetics

Synthetic peptides that mimic neurotrophic factors offer advantages over full-length proteins including improved stability and BBB penetration.^[5] [@winblad2012]

• BDNF-mimetic peptides: Small peptides derived from brain-derived neurotrophic factor that activate TrkB signaling without the full protein's instability.^[6]
• NGF-mimetic peptides: Peptide analogs of nerve growth factor for cholinergic neuron support in AD.^[7]
• GDNF-mimetic peptides: Glial cell line-derived neurotrophic factor peptides for dopaminergic neuron protection in PD.^[8]
• CDNF/MANF peptides: Cerebral dopamine neurotrophic factor peptides showing promise in PD models.^[9]

Amyloid-Targeting Peptides

Designed to bind, inhibit aggregation, or clear pathological protein aggregates.^[10] [@wiesehan2003]

Antimicrobial Peptides (AMPs) with Neuroprotective Properties

Some AMPs exhibit neuroprotective and immunomodulatory effects:^[11] [@cooper2021]

• LL-37: Human cathelicidin with anti-inflammatory properties in the CNS
• Human β-defensins: Modulate microglial activation
• Protegrins: Membrane-stabilizing properties

Clinical Applications by Disease

Alzheimer's Disease

Peptide Vaccines (Active Immunization)

• CAD106: [Aβ](/proteins/amyloid-beta)-mimetic peptide conjugated to virus-like particle; Phase 2 completed with acceptable safety profile.^[12]
• ACI-35: Liposome-based Aβ vaccine; Phase 2 ongoing.
• UB-311: Multi-epitope peptide vaccine; Phase 2 in early AD.

Anti-Aβ Peptide Approaches

• D-peptides: Enantiomeric peptides resistant to proteolysis that bind Aβ oligomers.^[13]
• Cyclic peptides: Constrained peptides with improved binding to Aβ aggregates.

[BACE1](/entities/bace1) Inhibitor Peptides

• Peptide-based transition-state analogs that inhibit β-secretase activity.
• Limited clinical success due to off-target effects and poor PK.^[14]

Neuroprotective Peptides

• NAP (NAPVSIPQ): Activity-dependent neuroprotective protein fragment; showed mixed results in clinical trials.^[15]
• Davanatide: GLP-1 mimetic peptide; Phase 2 for AD ongoing.

Parkinson's Disease

α-Synuclein Targeting Peptides

• Peptide inhibitors: KLVFF-like sequences adapted for α-synuclein aggregation.^[16]
• Molecular tweezers: Peptide-based compounds that sequester α-synuclein oligomers.

Neurotrophic Peptide Delivery

• GDNF-peptide conjugates: Enhanced BBB penetration for striatal delivery.
• CDNF peptide fragments: Smaller, more deliverable neurotrophic peptides.

Gene Delivery Peptides

• CPPs conjugated to GBA1-encoding mRNA for enzyme replacement in GBA-PD.

ALS and Motor Neuron Disease

SOD1-Mimetic Peptides

• Synthetic peptides that recapitulate superoxide dismutase activity.^[17]

Anti-Excitotoxicity Peptides

• [NMDA](/entities/nmda-receptor) receptor modulating peptides to reduce glutamate toxicity.

[TDP-43](/mechanisms/tdp-43-proteinopathy) Targeting

• Peptides that prevent TDP-43 aggregation and restore nuclear localization.

Advantages of Peptide Therapeutics

Limitations and Challenges

Administration Routes

Emerging Technologies

Peptide Cyclization

Cyclization improves metabolic stability and binding affinity:^[18]

• Head-to-tail cyclization: Backbone cyclized peptides
• Disulfide bridges: Stapled peptides
• Click chemistry: Triazole-linked cyclic peptides

Stapled Peptides

Hydrocarbon-stapled peptides show improved helicity, protease resistance, and cell penetration.^[19] Applications include:

• p53-MDM2 interaction inhibitors for neuroprotection
• BCL-2 family protein modulators

Peptide-Drug Conjugates (PDCs)

Peptides conjugated to small molecule drugs for targeted delivery:^[20]

• Homing peptides for brain-specific targeting
• CPP-drug conjugates for intracellular delivery

Clinical Pipeline Summary

Background

The study of Peptide Based Therapeutics For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Immunotherapy](/therapeutics/immunotherapy-neurodegeneration)
• Alpha-Synuclein Immunotherapy
• [Tau Immunotherapy](/therapeutics/tau-immunotherapy)
• [Neuroprotection](/mechanisms/neuroprotection)
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration)
• [Intranasal Drug Delivery](/mechanisms/intranasal-drug-delivery)
• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• [BDNF](/proteins/bdnf)
• GLP-1 Receptor Agonists